2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178796
    PROTAC LRRK2 Degrader-4 2839664-99-0 98%
    PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC50 of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation.
    PROTAC LRRK2 Degrader-4
  • HY-178797
    PROTAC LRRK2 Degrader-3 3080678-98-1 98%
    PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC50 of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation.
    PROTAC LRRK2 Degrader-3
  • HY-178826
    LSD1-IN-45 98%
    LSD1-IN-45 is an LSD1 inhibitor and a ligand for the target protein for PROTAC. LSD1-IN-45 can be used to synthesize PROTAC LD-110 (HY-178825).
    LSD1-IN-45
  • HY-178850
    TJN-331 219964-53-1 98%
    TJN-331 is a potent and orally active TGF-β1 Inhibitor. TJN-331 ameliorates anti-glomerular basement membrane (GBM) nephritis in rats by inhibitng TGF-β1 production, thereby reducing extracapillary proliferation in glomeruli. TJN-331 inhibits mesangial expansion in experimental IgA nephropathy in ddY mice. TJN-331 can be used for the research of nephritis and IgA nephropathy.
    TJN-331
  • HY-178885
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid TFA 98%
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid (TFA) (Compound H1) is a Methamphetamine hapten.(S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid (TFA) can be coupled to the BSA, Keyhole limpet hemocyanin molecule. The immunoconjugate H1-KLH strongly induces an antibody response.
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid TFA
  • HY-178913
    Tyk2-IN-23 2734918-75-1
    Tyk2-IN-23 is a potent, orally active, selective TYK2 inhibitor (IC50 = 18 nM), exhibiting more than > 70-fold selectivity over JAK1/2/3 isoforms. Tyk2-IN-23 potently inhibits p-STAT3 in TYK2-dependent signaling activated by IFN-α and IL-10. Tyk2-IN-23 potently inhibits IFN-α-induced STAT1 phosphorylation in H9 cells. Tyk2-IN-23 can be used for the study of alopecia areata and allergic Rhinitis.
    Tyk2-IN-23
  • HY-178915
    ITA-5 2374162-36-2
    ITA-5 is a TBK1 inhibitor based on the structure of itaconic acid. can significantly inhibit the secretion of IFN-β. ITA-5 can inhibit the phosphorylation of TBK1, IRF3, and STAT1. ITA-5 can be used for research on autoimmune diseases and excessive inflammation.
    ITA-5
  • HY-178916
    ITA-9
    ITA-9 is a TBK1 inhibitor based on the structure of itaconic acid. ITA-9 can inhibit the IFN-I signaling pathway. ITA-9 can inhibit the phosphorylation of TBK1, IRF3, and STAT1. ITA-9 can be used for research on inflammatory reactions and tissue damage.
    ITA-9
  • HY-178919
    N-19004 2996841-28-0
    N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa.
    N-19004
  • HY-178926
    RAGE406R 3034560-21-6
    RAGE406R is an orally active RAGE-DIAPH1 interaction antagonist. RAGE406R can bind to ctRAGE and prevent the formation of the RAGE-DIAPH1 complex and inhibit its interaction. RAGE406R can reduce the expression of CCL2, TNF, and IL-6 in THP1 cells. RAGE406R suppresses delayed-type hypersensitivity in T2D mice. RAGE406R can be used for the study of diabetes.
    RAGE406R
  • HY-178928
    KV1.3-IN-3
    KV1.3-IN-3 (Compound 13a) is a KV1.3 channel inhibitor. KV1.3-IN-3 decreases the Kv1.3 peak current amplitude by more than 80%. KV1.3-IN-3 exhibits excellent pharmacological properties and safety. KV1.3-IN-3 can be used for the study of autoimmunity disease.
    KV1.3-IN-3
  • HY-178935
    α-Amylase-IN-14 1099611-82-1
    α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an α-amylase inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes.
    α-Amylase-IN-14
  • HY-178936
    JAK2-IN-15 3094174-82-7
    JAK2-IN-15 is an orally active, potent, selective JAK2 inhibitor (IC50 = 1.17 nM). JAK2-IN-15 can inhibit the AK2-STAT signaling pathway. JAK2-IN-15 significantly improves key pathological indicators such as hematocrit and splenomegaly in an Epoetin beta (HY-114134) (rhEPO)-induced mouse model. JAK2-IN-15 can be used for the study of Polycythemia Vera (PV).
    JAK2-IN-15
  • HY-178945
    KOR agonist 7
    KOR agonist 7 (Compound 29) is a highly selective κ-opioid receptor (KOR) agonist with a Ki of 138 nM. KOR agonist 7 shows no activity at μ- and δ-opioid receptors or σ1 receptor, and exhibits extremely low affinity for σ2 receptor (Ki = 2.8 μM). KOR agonist 7 significantly reduces the secretion of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, while increasing the production of the anti-inflammatory cytokine IL-10. KOR agonist 7 downregulates the expression of the pro-inflammatory M1 macrophage marker CD80 and upregulates the anti-inflammatory M2 macrophage marker CD163. KOR agonist 7 holds potential for applications in analgesia and immune modulation.
    KOR agonist 7
  • HY-178950
    Hck-IN-3 3115216-60-6 98%
    Hck-IN-3 (compound 2D) is an orally effective inhibitor targeting HCK (KD = 3.92 μM). Hck-IN-3 can inhibit the release of NO. Hck-IN-3 has an IC50 of 6.52 μM in RAW264.7 cells. Hck-IN-3 can inhibit the release of TNF-α, IL-6, and IL-1β in a concentration dependent manner. Hck-IN-3 downregulates the protein expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1β in a concentration dependent manner. Hck-IN-3 can be used for research on acute non traumatic inflammatory conditions.
    Hck-IN-3
  • HY-178951
    STING-IN-17 3069635-58-8 98%
    STING-IN-17 (compound 10a) is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury.
    STING-IN-17
  • HY-178953
    NLRP3-IN-84
    NLRP3-IN-84 (Compound 32) is a NLRP3 inflammasome inhibitor. NLRP3-IN-84 can interfere with the oligomerization process of NLRP3 by inhibiting the activity of NLRP3 ATPase (IC50 = 158.4 nM). NLRP3-IN-84 inhibits Caspase-1 (IC50 = 27.7 nM), IL-1β release (PBMC: IC50 = 19.5 nM; mPBMC: IC50 = 24.2 nM), and ASC plaque formation (IC50 = 131 nM). NLRP3-IN-84 has no inhibitory activity on NLRC4 and AIM2 inflammasomes. NLRP3-IN-84 exhibits significant in vivo anti-inflammatory effects in a mouse acute peritonitis model. NLRP3-IN-84 can be used for the study of NLRP3-related inflammatory diseases.
    NLRP3-IN-84
  • HY-178958
    PPAR agonist 7 3122526-69-3 98%
    PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes.
    PPAR agonist 7
  • HY-178959
    FXR agonist 13
    FXR agonist 13 is a selective, orally active, potent FXR agonist (EC50 = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (KD = 14.74 μM). FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH).
    FXR agonist 13
  • HY-178966
    STING agonist-48 3027712-31-5
    STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC50 = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases.
    STING agonist-48
Cat. No. Product Name / Synonyms Application Reactivity